Literature DB >> 17661144

Lower recurrence rate for Limberg vs. V-Y flap for pilonidal sinus.

Haluk R Unalp1, Hayrullah Derici, Erdinc Kamer, Okay Nazli, Mehmet Ali Onal.   

Abstract

PURPOSE: Pilonidal sinus is a disease that does not have a standardized surgical treatment method. This study was designed to compare the outcomes of Limberg fasciocutaneous transposition and V-Y fasciocutaneous advancement flaps in the treatment of patients with pilonidal sinus.
METHODS: A total of 111 patients (98 males; 88.3 percent; mean age, 27.1 years) who received reconstruction after pilonidal sinus excision in our clinics with Limberg flap (Group 1, n = 66, 59.5 percent) or V-Y flaps (Group 2, n = 45, 40.5 percent) between 1997 and 2004 were investigated retrospectively.
RESULTS: No significant difference was detected between Groups 1 and 2 in terms of gender, history of infection or abscess, mean duration of operation, requirement for analgesics, wound-related complications, such as necrosis, seroma, and infection, and average time off work. Mean follow-up periods were 45.4 vs. 48.8 months in Group 1 and Group 2, respectively (P = 0.337). On the other hand, rate of recurrence was significantly lower in Group 1 (n = 1, 1.5 percent) compared with Group 2 (n = 5, 11.1 percent; P = 0.039).
CONCLUSIONS: We conclude that, if the defect is to be reconstructed with a flap in pilonidal sinus cases, reconstruction with Limberg flap should be preferred over reconstruction with V-Y flap because of its lower rate of recurrence.

Entities:  

Mesh:

Year:  2007        PMID: 17661144     DOI: 10.1007/s10350-007-0276-8

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  9 in total

1.  Retrospective review of pilonidal sinus patients with early discharge after Limberg flap procedure.

Authors:  Fatih Altintoprak; Kemal Gundogdu; Tolga Ergonenc; Enis Dikicier; Guner Cakmak; Fehmi Celebi
Journal:  Int Surg       Date:  2014 Jan-Feb

2.  Comparison of the Limberg flap and bilateral gluteus maximus advancing flap following oblique excision for the treatment of pilonidal sinus disease.

Authors:  Murat Yildar; Faruk Cavdar
Journal:  Surg Today       Date:  2013-10-23       Impact factor: 2.549

3.  Outcomes in the repair of pilonidal sinus disease excision wounds using a parasacral perforator flap.

Authors:  M R Venus; O G Titley
Journal:  Ann R Coll Surg Engl       Date:  2012-01       Impact factor: 1.891

4.  A New Oval Advancement Flap Design for Reconstruction of Pilonidal Sinus Defect.

Authors:  Enver Arpaci; Serdar Altun; Erkan Orhan; Atilla Eyuboglu; Nilgun Markal Ertas
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

5.  S-plasty for pilonidal disease: modified primary closure reducing tension.

Authors:  Jae Keun Kim; Jin Cheol Jeong; Joung Bum Lee; Kuk Hyun Jung; Byong Ku Bae
Journal:  J Korean Surg Soc       Date:  2012-01-27

6.  Comparision of the Limberg flap with the V-Y flap technique in the treatment of pilonidal disease.

Authors:  Fatih Altintoprak; Enis Dikicier; Yusuf Arslan; Taner Ozkececi; Gokhan Akbulut; Osman Nuri Dilek
Journal:  J Korean Surg Soc       Date:  2013-07-25

7.  Common surgical procedures in pilonidal sinus disease: A meta-analysis, merged data analysis, and comprehensive study on recurrence.

Authors:  V K Stauffer; M M Luedi; P Kauf; M Schmid; M Diekmann; K Wieferich; B Schnüriger; D Doll
Journal:  Sci Rep       Date:  2018-02-15       Impact factor: 4.379

8.  Impact of geography and surgical approach on recurrence in global pilonidal sinus disease.

Authors:  Dietrich Doll; Andriu Orlik; Katharina Maier; Peter Kauf; Marco Schmid; Maja Diekmann; Andreas P Vogt; Verena K Stauffer; Markus M Luedi
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

9.  Comparison of Limberg flap and excision and primary closure of pilonidal sinus disease, in terms of quality of life and complications.

Authors:  Ahmet Serdar Karaca; Rıdvan Ali; Muzaffer Capar; Sezar Karaca
Journal:  J Korean Surg Soc       Date:  2013-10-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.